CureVac Trials - LARVOL Sigma

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

BI 1361849 / CureVac

2014-004959-30: Clinical trial to compare the anti-cancer vaccine BI 1361849 (CV9202) versus placebo in patients with non-small cell lung cancer after completion of chemoradiation therapy

Ongoing

317

Europe

BI 1361849, BI 1361849, Powder and solvent for solution for injection

Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Norway KS, Boehringer Ingelheim España, S.A., SCS Boehringer Ingelheim Comm.V, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharma GmbH, Boehringer Ingelheim España, S.A., SCS Boehringer Ingelheim Comm.V

Non small cell lung cancer stage III after concurrent chemoradiation therapy, Non small-cell lung cancer, Diseases [C] - Cancer [C04]

2015-001477-41: BI 1361849 (CV9202) + afatinib compared with placebo + afatinib in first-line NSCLC harbouring common EGFR mutations BI 1361849 (CV9202) + afatinib comparado con placebo + afatinib como tratamiento de primera línea en pacientes con NSCLC portadores de mutaciones comunes del EGFR.

Ongoing

1/2

120

Europe

BI 1361849, Afatinib, BI 1361849, BIBW 2992, Powder and solvent for solution for injection, Film-coated tablet, GIOTRIF 20 mg film-coated tablets, GIOTRIF 30 mg film-coated tablets, GIOTRIF 40 mg film-coated tablets

Boehringer Ingelheim España, S.A., Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim España, S.A., Boehringer Ingelheim Pharma GmbH & Co. KG

Advanced non-small cell lung cancer (adenocarcinoma) stage IV. Cáncer de pulmón no microcítico metastásico (adenocarcinoma) estadio IV ., Advanced lung cancer with metastases. Cáncer de pulmón avanzado con metástasis., Diseases [C] - Cancer [C04]

CV8102 / CureVac

NCT03291002: Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC

Active, not recruiting

Europe, RoW

CV8102, CV8102 + anti-PD-1 therapy

CureVac AG, Syneos Health, Cromos Pharma LLC

Melanoma (Skin), Squamous Cell Carcinoma of the Skin, Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Adenoid Cystic

10/22

02/23

Hepavac (IMA970A) / Immatics, CureVac

NCT06218511: A Phase I Trial of IMA970A Plus Montanide in Combination with Durvalumab (anti-PD-L1)

Recruiting

Europe

Peptide-based hepatocellular carcinoma vaccine IMA970A, Durvalumab, Montanide (Adjuvant)

National Cancer Institute, Naples

Hepatocellular Carcinoma

06/25

11/26

zorecimeran (CV07050101) / CureVac

2021-001735-10: COVID-19: A study to learn about the safety, local and systemic reactions, and the immune responses to the SARS-CoV-2 mRNA Vaccine (CVnCoV) when given to participants 45 years or older who have either a solid tumor or blood cancer and are already taking or about to start systemic anticancer therapy

Ongoing

620

Europe

CVnCoV, CV07050101, Solution for injection

Bayer AG, Bayer AG

Vaccination for prophylaxis of coronavirus disease 2019 (COVID-19), Vaccination for prevention of coronavirus disease 2019 (COVID-19), Diseases [C] - Virus Diseases [C02]

NCT04834869: COVID-19 Vaccines Safety Tracking (CoVaST)

Recruiting

N/A

30000

Europe, Canada, US, RoW

BNT162b2, mRNA-1273, AZD1222, CoronaVac, Sinopharm, Gam-COVID-Vac, JNJ-78436735, CVnCoV, NVX-CoV2373, BBV152

Masaryk University

Adverse Reaction to Vaccine, COVID19 Vaccine

12/25

12/26

FRAME-001 / CureVac

2021-003166-12: FRAME-001 personalized vaccine in NSCLC FRAME-001 gepersonaliseerd vaccin in Niet- Kleincellig Long Carcinoom

Not yet recruiting

Europe

FRAME-001, FRAME-001, Solution for injection

Frame Pharmaceuticals B.V., Frame Pharmaceuticals B.V.

Advanced Non- small cell lung carcinoma (NSCLC) Gevorderd niet- kleincellig long carcinoom, Advanced Non- small cell lung carcinoma (NSCLC) Gevorderd niet- kleincellig long carcinoom, Diseases [C] - Cancer [C04]

FRAME-001, NCT04998474 / 2021-003166-12: Personalized Vaccine in NSCLC

Not yet recruiting

Europe

FRAME-001 personalized vaccine

Frame Pharmaceuticals B.V., Erasmus Medical Center, The Netherlands Cancer Institute, University Medical Center Groningen, Leiden University Medical Center

Non Small Cell Lung Cancer

01/24

07/24

GSK4396687 / GSK

NCT05260437: Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants

Completed

CV2CoV (2 µg), CV2CoV (4 µg), CV2CoV (8 µg), CV2CoV (12 µg), CV2CoV (16 µg), CV2CoV (20 µg)

GlaxoSmithKline, CureVac

COVID-19, SARS-CoV-2

03/23

quadrivalent influenza mRNA vaccine (CVSQIV) / CureVac, GSK

NCT05252338: A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVSQIV in Healthy Adults

Completed

240

RoW

CVSQIV

CureVac, GlaxoSmithKline

Influenza

09/22

GSK4382276 / GSK

NCT06431607: A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults

Active, not recruiting

843

Flu Seasonal mRNA Formulation 1, GSK4382276A, Flu Seasonal mRNA Formulation 2, Flu Seasonal mRNA Formulation 3, Flu Seasonal mRNA Formulation 4, Flu Seasonal mRNA Formulation 5, Flu Seasonal mRNA Formulation 6, Flu Seasonal mRNA Formulation 7, Flu Seasonal mRNA Formulation 8, Active Comparator 1, Active Comparator 2, Flu Seasonal mRNA Formulation 9, Flu Seasonal mRNA Formulation 10, Active Comparator 3, Active Comparator 4

GlaxoSmithKline

Influenza, Human

11/24

06/25

NCT05823974: A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults

Completed

1/2

1268

Europe, Canada, US, RoW

Flu mRNA, GSK4382276A, Control 1, Control 2

GlaxoSmithKline, CureVac

Influenza, Human

07/24

NCT05446740: A Study on the Safety, Reactogenicity and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults

Completed

324

Europe, Canada

GSK4382276A Dose level 1, Flu mRNA, GSK4382276A Dose level 2, GSK4382276A Dose level 3, GSK4382276A Dose level 4, GSK4382276A Dose level 6, GSK4382276A Dose level 7, GSK4382276A Dose level 8, GSK4382276A Dose level 9, GSK4382276A Dose level 10, GSK4382276A Dose level 11, FDQ21A-NH, FDQ22A-NH

GlaxoSmithKline, CureVac

Influenza, Human

03/24

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

BI 1361849 / CureVac

2014-004959-30: Clinical trial to compare the anti-cancer vaccine BI 1361849 (CV9202) versus placebo in patients with non-small cell lung cancer after completion of chemoradiation therapy

Ongoing

317

Europe

BI 1361849, BI 1361849, Powder and solvent for solution for injection

Non small cell lung cancer stage III after concurrent chemoradiation therapy, Non small-cell lung cancer, Diseases [C] - Cancer [C04]

Ongoing

1/2

120

Europe

Boehringer Ingelheim España, S.A., Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim España, S.A., Boehringer Ingelheim Pharma GmbH & Co. KG

CV8102 / CureVac

NCT03291002: Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC

Active, not recruiting

Europe, RoW

CV8102, CV8102 + anti-PD-1 therapy

CureVac AG, Syneos Health, Cromos Pharma LLC

Melanoma (Skin), Squamous Cell Carcinoma of the Skin, Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Adenoid Cystic

10/22

02/23

Hepavac (IMA970A) / Immatics, CureVac

NCT06218511: A Phase I Trial of IMA970A Plus Montanide in Combination with Durvalumab (anti-PD-L1)

Recruiting

Europe

Peptide-based hepatocellular carcinoma vaccine IMA970A, Durvalumab, Montanide (Adjuvant)

National Cancer Institute, Naples

Hepatocellular Carcinoma

06/25

11/26

zorecimeran (CV07050101) / CureVac

Ongoing

620

Europe

CVnCoV, CV07050101, Solution for injection

Bayer AG, Bayer AG

Vaccination for prophylaxis of coronavirus disease 2019 (COVID-19), Vaccination for prevention of coronavirus disease 2019 (COVID-19), Diseases [C] - Virus Diseases [C02]

NCT04834869: COVID-19 Vaccines Safety Tracking (CoVaST)

Recruiting

N/A

30000

Europe, Canada, US, RoW

BNT162b2, mRNA-1273, AZD1222, CoronaVac, Sinopharm, Gam-COVID-Vac, JNJ-78436735, CVnCoV, NVX-CoV2373, BBV152

Masaryk University

Adverse Reaction to Vaccine, COVID19 Vaccine

12/25

12/26

FRAME-001 / CureVac

2021-003166-12: FRAME-001 personalized vaccine in NSCLC FRAME-001 gepersonaliseerd vaccin in Niet- Kleincellig Long Carcinoom

Not yet recruiting

Europe

FRAME-001, FRAME-001, Solution for injection

Frame Pharmaceuticals B.V., Frame Pharmaceuticals B.V.

FRAME-001, NCT04998474 / 2021-003166-12: Personalized Vaccine in NSCLC

Not yet recruiting

Europe

FRAME-001 personalized vaccine

Frame Pharmaceuticals B.V., Erasmus Medical Center, The Netherlands Cancer Institute, University Medical Center Groningen, Leiden University Medical Center

Non Small Cell Lung Cancer

01/24

07/24

GSK4396687 / GSK

NCT05260437: Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants

Completed

CV2CoV (2 µg), CV2CoV (4 µg), CV2CoV (8 µg), CV2CoV (12 µg), CV2CoV (16 µg), CV2CoV (20 µg)

GlaxoSmithKline, CureVac

COVID-19, SARS-CoV-2

03/23

quadrivalent influenza mRNA vaccine (CVSQIV) / CureVac, GSK

NCT05252338: A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVSQIV in Healthy Adults

Completed

240

RoW

CVSQIV

CureVac, GlaxoSmithKline

Influenza

09/22

GSK4382276 / GSK

NCT06431607: A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults

Active, not recruiting

843

GlaxoSmithKline

Influenza, Human

11/24

06/25

NCT05823974: A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults

Completed

1/2

1268

Europe, Canada, US, RoW

Flu mRNA, GSK4382276A, Control 1, Control 2

GlaxoSmithKline, CureVac

Influenza, Human

07/24

NCT05446740: A Study on the Safety, Reactogenicity and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults

Completed

324

Europe, Canada

GlaxoSmithKline, CureVac

Influenza, Human

03/24



	Diseases Companies Products Productz Mechanisms of Action Sites